bookmaker en français
The holidays are just about here, and if you're still scrambling for last-minute gifts , you don't have to break the bank to get something good. If someone on your list is a fan of using Amazon Alexa around the house and is looking to upgrade their home with some smart devices (or if you want to jazz up your own home's technology), you won't want to miss this offer. Hey, did you know? CNET Deals texts are free, easy and save you money . Right now, you can get the Amazon Echo Dot with the Wiz A19 LED smart light bulb for just $25 , saving you almost 60% off the regular bundle price. Like other Amazon deals, we expect this one to fluctuate, so we suggest acting fast if you want to be sure to get this bundled price. Keep in mind this deal only applies to the charcoal color option for the Echo Dot. If you want the deep sea blue or glacier white, it'll cost you $30, which is still a significantly discounted price. The Echo Dot is the smallest smart speaker in Amazon's lineup. You can use it to stream music, set alarms, check the weather, shop and more using just your voice. And this latest version offers a number of upgrades and improvements over previous models, offering better sound quality overall. As for the smart bulb, once you sync the two devices, you'll be able to turn your lights on and off with Alexa, too, as well as set schedules or fine-tune your lighting to your preferences with the app. If you want more inspiration, check out our roundup of other smart home deals happening now. We've also rounded up a list of the best Amazon tech deals under $100 if you want to shop around for other budget-friendly devices. Why this deal matters A bundle like this hasn't gone on sale since the end of summer. The last time we saw it discounted was during Amazon's Labor Day sale event in September. But even then, it was priced at $30. Right now, it's only $25, beating that previous low price. At that time, the Echo Dot was bundled with a Sengled light bulb, and this time it is with a comparable Wiz bulb. We don't believe the brand change affects the overall value here, so with the new price drop, we think this is a solid buy. Will this item arrive in time for Christmas? If you're ordering this as a holiday gift , you probably want to know if it's going to arrive on time. With Christmas and Hanukkah both taking place on Dec. 25 this year, and Kwanzaa kicking off the day after, it's important to note shipping deadlines for USPS, FedEx, UPS, Amazon and others . Guaranteed shipping deadlines at some of these delivery companies arrived as soon as Dec. 16, with others offering expedited services that may allow you to order as late as Dec. 23 or even Dec. 24. Where delivery is no longer possible, be sure to assess your in-store pickup options or check out these great digital deals for the holidays . This smart bundle will arrive before Christmas, according to Amazon. CNET is always covering a wide array of deals on tech products and much more. Start with the hottest sales and discounts on the CNET Deals page , and sign up for the CNET Deals Text to get daily deals sent straight to your phone. Add the free CNET Shopping extension to your browser for real-time price comparisons and cash-back offers. And peruse our gift guide , which includes a full range of ideas for birthdays, anniversaries and more.
In an exclusive interview with The AJN’s director Anna Pasternak in Israel, former justice minister Ayelet Shaked has accused the Australian government of being “confused between good and evil” after she was denied a visa to travel to Australia. Shaked was invited to Australia by the Australia/Israel and Jewish Affairs Council (AIJAC) to speak at a series of events across Melbourne, Canberra and Sydney, but her visa application was rejected on the grounds that she might “incite discord in the Australian community”. Shaked was last granted a visa to attend a women’s event in Australia in February 2023. “It’s just a brutal political act,” Shaked told The AJN. “The Israeli Foreign Ministry and the Ministry of the Interior informed the Albanese government that if they did not reverse their decision, they will consider re-examining the current visa waiver program we have with Australia. “It’s undemocratic and it has never happened to me before from any other country.” Shaked said Israelis are aware that the Australian government is “pretty hostile” towards Israel and that the decision to deny her a visa is more embarrassing for the Albanese government than it is for her. “It’s really shameful. The Australian government is confused between good and evil,” she said. “It is a political act committed against my country, so I’m not taking it personally. I think it mainly embarrasses them and it’s disgraceful for them.” “Countries that are allies, like Israel and Australia, cannot do such things,” said Shaked. “Australia and Israel have a very warm relationship, and we consider Australia as a strong ally of Israel, and it doesn’t matter who the government is. This government will be [an] antisemitic anecdote in the history of our bilateral relationship.” A spokesperson for Israel’s Ministry of Foreign Affairs said, “The Australian government’s decision to deny a visa to former Israeli minister Ayelet Shaked is unacceptable. The decision is deeply offensive and troubling, and will have a negative impact on Israel–Australia relations.” Shaked said she is disappointed not to be speaking to the community in Australia, while AIJAC executive director Colin Rubenstein condemned the visa refusal as “a disgraceful act of hostility towards a democratic ally”. “It is extraordinary that a government that refuses to take any meaningful action against an Iranian ambassador who effectively calls for genocide would act so undiplomatically towards a friend,” he said. “This will no doubt damage relations with Israel, a country from which Australia has received so many benefits. We believe this is a cynical attempt to appear even-handed in the wake of some refusals of visas for Palestinians who have ties to, or evidence-based support for terrorism.” President of the Zionist Federation of Australia Jeremy Leibler described the decision as “baffling and deeply offensive”. He highlighted Shaked’s role in “the most diverse and centrist Israeli government in history, which included an Israeli Arab party and minister”, and questioned the government’s inconsistency. “This refusal is particularly perplexing given that this very same government granted her a visa less than two years ago,” he said. Leibler also criticised the granting of a visa to a Palestinian reportedly linked to terrorist organisations, while barring a minister from a democratic ally. “Many Australians will rightly ask: what has changed within the government between then and now?” he added. Home Affairs Minister Tony Burke confirmed the application had been rejected, while opposition home affairs spokesman James Paterson said, “The Albanese government must explain why a former minister in a friendly government and someone they granted a visa to only two years ago is now such a threat they must be banned from Australia.”TJ Bamba led Oregon with 22 points and five assists in the Ducks' 78-68 victory over San Diego State on Wednesday in pool play of the Players Era Festival at Las Vegas. The Ducks (7-0) won both games in the "Power Group" and will play in the championship Saturday against the top team from the "Impact Group." San Diego State (3-2) will await its opponent for one of the secondary games Saturday. The matchups are based on seeding dependent on performance of the first two games. Bamba made 7 of 14 shots from the field, including 4 of 6 from 3-point range. Keeshawn Barthelemy had 16 points on 5-of-8 shooting from the field and hit 3 of 4 from beyond the arc. Nate Bittle finished with 11 points and nine rebounds, Brandon Angel 12 points and six rebounds and Jackson Shelstad paired 12 points with four assists. BJ Davis led San Diego State with 18 points before fouling out. Nick Boyd finished with 15 points on 6-of-9 shooting from the field, including 3-of-4 from beyond the arc. Neither team led by more than four points until Oregon scored nine unanswered to take a 34-27 lead with 2:20 left in the first half. Barthelemy started the run with a jumper and finished it with a 3-pointer. Oregon outscored San Diego State 16-4 in the last 4:23 of the half to take a 41-31 lead into the break. Bamba and Barthelemy combined for 20 points on 7-of-14 shooting in the first half. Boyd led San Diego State with 13 points, making all three of his 3-point attempts and going 5-of-6 overall. A 7-2 run for Oregon increased its advantage to 48-35 with 17:36 remaining, but San Diego State cut the lead to 56-53 with 10:58 left following a 9-0 run. A Bamba 3-pointer closed an 8-2 stretch with 4:15 remaining to increase Oregon's lead to 73-63. San Diego State did not get closer than eight points the rest of the way. Davis fouled out with 31 seconds left and Oregon leading 77-68. --Field Level Media
NEW YORK (AP) — A number of President-elect Donald Trump 's most prominent Cabinet picks and appointees have been targeted by bomb threats and “swatting attacks," Trump's transition team said Wednesday. The FBI said it was investigating. “Last night and this morning, several of President Trump’s Cabinet nominees and Administration appointees were targeted in violent, unAmerican threats to their lives and those who live with them," Trump transition spokesperson Karoline Leavitt said in a statement. She said the attacks ranged from bomb threats to swatting, in which attackers initiate an emergency law enforcement response against a target victim under false pretenses. The tactic has become a popular one in recent years. Leavitt said law enforcement and other authorities acted quickly to ensure the safety of those who were targeted and Trump and his transition team are grateful. Among those targeted were New York Rep. Elise Stefanik, Trump’s pick to serve as the next ambassador to the United Nations ; Matt Gaetz, Trump’s initial pick to serve as attorney general ; and former New York congressman Lee Zeldin, who has been tapped to lead the Environmental Protection Agency. Law enforcement officials are also looking into whether Susie Wiles, Trump’s incoming chief of staff, and Pam Bondi, the former Florida attorney general whom Trump has chosen as Gaetz’s replacement, and other incoming administration officials were also victims — as well as how each was targeted, according to a law enforcement official who spoke on condition of anonymity as the investigation continues. Wiles and Bondi did not immediately respond to requests for comment. The FBI said in a statement that it was “aware of numerous bomb threats and swatting incidents targeting incoming administration nominees and appointees" and was investigating with its law enforcement partners. The FBI added: "We take all potential threats seriously, and as always, encourage members of the public to immediately report anything they consider suspicious to law enforcement.” White House spokesperson Saloni Sharma said President Joe Biden had been briefed and the White House is in touch with federal law enforcement and Trump's transition team. Biden “continues to monitor the situation closely," Sharma said, adding the president and his administration “condemn threats of political violence.” Stefanik's office said that, on Wednesday morning, she, her husband, and their 3-year-old son were driving home from Washington for Thanksgiving when they were informed of a bomb threat to their residence in Saratoga County. Her office said “New York State, County law enforcement, and U.S. Capitol Police responded immediately with the highest levels of professionalism.” The New York State Police said a team was dispatched to sweep Stefanik’s home on Wednesday morning in response to the bomb threat but did not locate any explosive devices. The agency directed further questions to the FBI. Zeldin said in a social media post that he and his family had been threatened. “A pipe bomb threat targeting me and my family at our home today was sent in with a pro-Palestinian themed message,” he wrote on X . “My family and I were not home at the time and are safe. We are working with law enforcement to learn more as this situation develops.” Police in Suffolk County, Long Island, said emergency officers responded to a bomb threat Wednesday morning at an address listed in public records as Zeldin’s home and were checking the property. In Florida, the Okaloosa County sheriff’s office said on Facebook that it “received notification of a bomb threat referencing former Congressman Matt Gaetz’s supposed mailbox at a home in the Niceville area" around 9 a.m. Wednesday. While a family member resides at the address, the office said, Gaetz “is NOT a resident.” No threatening devices were found. Gaetz was Trump’s initial pick to serve as attorney general, but he withdrew from consideration after allegations that he paid women for sex and slept with underage women. Gaetz has vehemently denied any wrongdoing and said last year that a Justice Department investigation into sex trafficking allegations involving underage girls had ended with no federal charges against him. The threats follow a political campaign marked by disturbing and unprecedented violence. In July, a gunman opened fire at a Trump rally in Butler, Pennsylvania, grazing the then-candidate in the ear with a bullet and killing one of his supporters. The Secret Service later thwarted a subsequent assassination attempt at Trump's West Palm Beach, Florida, golf course when an agent spotted the barrel of a gun poking through a perimeter fence while Trump was golfing. Trump was also the subject of an Iranian murder-for-hire plot , with a man saying he had been tasked with planning the assassination of the Republican president-elect. Also this week, authorities arrested a man they say posted videos on social media threatening to kill Trump, according to court documents. In one video posted on Nov. 13, Manuel Tamayo-Torres threatened to shoot the former president while holding what appeared to be an AR-15 style rifle, authorities said Among the other videos he posted was one from an arena in Glendale, Arizona on Aug. 23, the same day Trump held a campaign rally there, according to court papers. An attorney for Tamayo-Torres did not immediately respond to a request for comment Wednesday. Public figures across the political spectrum have been targeted in recent years by hoax bomb threats and false reports of shootings at their homes. About a year ago the FBI responded to an uptick in such incidents at the homes of public officials, state capitols and courthouses across the country around the holidays. Many were locked down and evacuated in early January after receiving bomb threats. No explosives were found and no one was hurt. Some of those targeted last year were Georgia Lt. Gov. Burt Jones, Boston Mayor Michelle Wu and Ohio Attorney General Dave Yost. In Wu’s case, a male caller told police he had shot his own wife and tied another man up. When police and EMT responders arrived at the address given by the caller, they quickly realized it was the Boston mayor’s home. Wu, a Democrat, has also been targeted by many swatting calls since she took office in 2021. The judges overseeing the civil fraud case against Trump in New York and the criminal election interference case against him in Washington were both targeted earlier this year. Justice Department special counsel Jack Smith, who recently abandoned the two criminal cases he brought against Trump, was also the subject of a fake emergency call on Christmas Day last year. Earlier this year, schools, government buildings and the homes of city officials in Springfield, Ohio, received a string of hoax bomb threats after Trump falsely accused members of Springfield’s Haitian community of abducting and eating cats and dogs. And in 2022, a slew of historically Black colleges and universities nationwide were targeted with dozens of bomb threats, with the vast majority arriving during the celebration of Black History Month. The U.S. Capitol Police said in a statement Wednesday that anytime a member of Congress is the victim of a swatting' incident, “we work closely with our local and federal law enforcement partners.” The force declined to provide further details, in part to “minimize the risk of copy-cats.” Republican House Speaker Mike Johnson called the threats “dangerous and unhinged.” “This year, there was not just one but TWO assassination attempts on President Trump," he wrote on X . “Now some of his Cabinet nominees and their families are facing bomb threats.” He added: “It is not who we are in America.” ___ Richer reported from Washington. Associated Press writers Colleen Long and Eric Tucker in Washington, Scott Bauer in Madison, Wisconsin, and Anthony Izaguirre in Albany, New York, contributed to this report.Alas! Tougher sanctions loom for airport troublemakers
Dover Corp. stock underperforms Wednesday when compared to competitors despite daily gainsCMC Publishes 2024 Sustainability Report
Fresh off a fellowship in cardiovascular disease at Hahnemann University Hospital, a young cardiologist arrived in Pottsville at the Reading Railroad Station on East Norwegian Street in 1972. Dr. Muhammad M. Munir came to join Dr. Benjamin Platt, whom he met at Hahnemann, in Dr. Norman Wall’s practice in Pottsville. It was his first practice, in a place he’d hardly ever heard of, and he stayed for 52 years until retiring from the staff of Lehigh Valley Health Network in July. Munir is notable for his dedication, vision and contribution to the health care of Schuylkill County. “My patients were like family to me,” the 83-year-old retired physician said in a recent interview. “They were responsible for me staying here as long as I have.” In retirement, he maintains contact with some of his patients, making sure they are well taken care of. He continues to read medical journals, keeping abreast of the latest developments in cardiology. Dr. Munir was honored recently during a gala at Arrow Studio & Events in Pottsville, organized by his daughter, Farrah, a pediatric cardiologist at Mount Sinai Hospital in New York. Among the 135 guests was Dr. Abdul Wahhab, a colleague who practiced surgery in Pottsville for 42 years before retiring in 2015. A skilled artist whose work hangs in Lehigh Valley Hospital-Schuylkill, Wahhab presented Munir with a commemorative painting. In 1977, Munir converted a former A&P supermarket into a Medical Arts Building on Claude A. Lord Boulevard in Pottsville. Joining him as partners were doctors Platt, Wahhab, Abdul Rashid and Ghaffar A. Zafar. During his career, Munir was directly or indirectly responsible for recruiting 15 young doctors of various specialties to practice in Schuylkill County. The son of a postmaster, he grew up in Rawalpindi, Pakistan, at a time of political turmoil. One of seven children, he says his mother’s commitment to education is largely responsible for him becoming a doctor. After graduating from Nishtar Medical College in Multan, Pakistan, in 1964, he did residencies in Albany, the Bronx, London and Maimonides Medical Center in Brooklyn before securing a two-year fellowship at Hahnemann. Seeing himself as an old-style clinician, Munir spent much of his time in face-to-face encounters with patients. Rarely did he use a computer during a consultation. “Medicine is not strictly a science,” he contends, “there is an art to it.” In addition to his spouse, Misbah, Munir was joined by his children, Shawn, Farrah and Omar at the gala. He was particularly happy that so many of the nurses he worked with at the former Good Samaritan Hospital were able to attend the gala. Nurses, perhaps more than anyone in the medical profession, helped him throughout his career, he says. Long a resident of Howard Avenue in Pottsville, Munir currently lives in Cressona.CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.
- Previous: bookmaker download
- Next: bookmaker eu reviews
